9 Facts About HRT and Migraine That Neurologists and Gynecologists Need to Agree On
The women who message about this are often caught in the middle — their neurologist says avoid HRT, their gynaecologist says try it, and neither seems to know what the other has told them. What's maddening is that both can be right, depending entirely on which HRT and how it's given. That nuance deserves a proper conversation, not a tug-of-war between two specialists.
Learn more about Rose →Estrogen withdrawal — not high estrogen — is the most common migraine trigger in perimenopause
The sharp drop in estrogen that triggers a menstrual migraine is the same mechanism driving the increased migraine frequency many women notice in perimenopause, when cycles become erratic and estrogen fluctuates wildly. It is the falling edge of the estrogen curve, not peak levels, that activates trigeminal pain pathways and lowers the brain's migraine threshold. This is why stabilising estrogen — rather than removing it — is the physiologically logical approach for many perimenopausal migraineurs.
Oral HRT creates peaks and troughs that can mimic the withdrawal cycle
Oral estradiol is absorbed through the gut and metabolised by the liver before it reaches circulation, producing a pronounced rise-and-fall pattern in blood levels over 24 hours. For women with migraine, this daily mini-fluctuation can be enough to trigger attacks in a similar way to the pre-menstrual estrogen drop. This is one of the central reasons the route of administration matters so much in this population, and why oral is rarely the first-choice recommendation for women with migraine-related hormone sensitivity.
Transdermal estradiol produces stable blood levels and is associated with fewer migraine attacks
Patches, gels, and sprays deliver estradiol directly into the bloodstream through the skin, bypassing the liver and producing far steadier plasma concentrations than oral preparations. Clinical studies and headache society guidelines consistently identify transdermal estradiol as the preferred route for women with migraine, precisely because stable levels remove the withdrawal trigger. A Cochrane-reviewed body of evidence supports transdermal estradiol as genuinely migraine-neutral or even migraine-suppressing in postmenopause, in contrast to the more variable picture with oral forms.
The type of progestogen added to HRT also matters for migraine
Combined HRT requires a progestogen to protect the uterine lining, but not all progestogens behave the same way neurologically. Synthetic progestins — particularly norethisterone and levonorgestrel — have been associated with worsening headache in susceptible women, possibly due to their androgenic activity and effects on serotonin pathways. Micronised progesterone, which is structurally identical to the body's own progesterone and acts as a GABA-A receptor positive modulator, is generally better tolerated by women with migraine, though evidence is still accumulating.
Migraine with aura is a separate clinical risk category and must be distinguished from migraine without aura
Migraine with aura carries an independently elevated risk of ischaemic stroke, and this risk interacts with estrogen in ways that are not fully understood but are taken seriously by both neurology and cardiology guidelines. Combined oral contraceptives are contraindicated in migraine with aura because of stroke risk, but the same blanket restriction does not automatically apply to low-dose transdermal HRT used in menopause, where systemic estrogen levels are lower and venous thromboembolism risk via transdermal routes is not significantly elevated. Women with migraine with aura deserve an individualised conversation, not a blanket refusal.
Menopause can improve migraine — but the transition itself often makes it temporarily worse
Population data consistently show that migraine improves after natural menopause in the majority of women, particularly those whose attacks were historically linked to the menstrual cycle. However, perimenopause — the 4-to-10-year transition period with its chaotic hormonal swings — is when migraine frequency and severity often peak. Clinicians who only consider the post-menopausal endpoint miss the window in which intervention could most meaningfully reduce a woman's migraine burden.
Continuous combined HRT tends to be better tolerated for migraine than cyclical regimens
Cyclical HRT — where progestogen is taken for 10-14 days each month — reintroduces a hormone withdrawal event at the end of each progestogen phase that can trigger headache in a pattern eerily similar to menstrual migraine. Continuous combined regimens, where both estradiol and progestogen are taken daily without a break, eliminate this cyclical fluctuation and are generally preferred once a woman is suitable for them, typically at least one year post-menopause. The Mirena IUS, which delivers levonorgestrel locally to the uterus with minimal systemic absorption, is another option that some women with migraine tolerate well.
There is no robust evidence that HRT increases overall migraine frequency in postmenopausal women when delivered transdermally
A persistent clinical myth holds that HRT categorically worsens migraine, but the evidence base for this is largely drawn from older studies using oral conjugated equine estrogens, not modern transdermal estradiol. Prospective data and expert consensus from the International Headache Society and the British Menopause Society both distinguish between oral and transdermal preparations, and neither body recommends withholding transdermal HRT from postmenopausal women with migraine as a blanket policy. The fear-based refusal of HRT on migraine grounds, without considering formulation, represents an evidence gap that is costing women quality of life.
Dose titration and trial periods are essential — the first HRT formulation is rarely the final answer
Because migraine sensitivity to hormonal fluctuation varies enormously between individuals, the clinical approach should be iterative: start low, stabilise, and adjust based on headache diary data over a minimum of three months. Women who experience worsening migraine on one formulation should not conclude that HRT is incompatible with their neurology — a switch in route, a change in progestogen, or a reduction in dose may resolve the problem entirely. Keeping a headache diary before and during HRT initiation is one of the most practical tools available, turning subjective experience into data that guides clinician decision-making.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.